αGalCer-RBD

αGalCer-RBD is a self-adjuvanting vaccine candidate that conjugates the iNKT cell agonist α-Galactosylceramide to the SARS-CoV-2 RBD domain. It induces robust immunity by generating RBD-specific, cytokine-producing T cells, as demonstrated in preclinical in vivo studies against SARS-CoV-2 and its variants.